Trending Articles

article thumbnail

Collaboration aims to reduce animal use in drug safety testing

Broad Institute

Collaboration aims to reduce animal use in drug safety testing By Leah Eisenstadt July 29, 2025 Breadcrumb Home Collaboration aims to reduce animal use in drug safety testing OASIS consortium is evaluating omics tools in cells, including Cell Painting and transcriptomics, to predict liver toxicity of potential new medicines and agrochemicals. By Leah Eisenstadt July 29, 2025 Credit: Axiom Bio, via Cell Painting Gallery (CC0 License) Members of the OASIS Consortium are employing the Cell Painting

article thumbnail

Research progress on covalent inhibitors targeting alkaline amino acids

Covalent Modifiers

Bing Zhao, Sha Xu, Shiqing Zhou, Xiangru Jiang, Ailin Jiang, Hongrui Lei, Xin Zhai Bioorganic Chemistry, 163, 2025, 108800, [link] [link] the past two decades, covalent inhibitors have undergone a remarkable resurgence in drug discovery. Currently, targeting non-catalytic cysteine residues with acrylamide and other α,β-unsaturated carbonyl compounds is a predominate strategy, especially in the protein kinase field.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

State-of-the-art covalent virtual screening with AlphaFold3

Covalent Modifiers

Yoav Shamir, Nir London bioRxiv 2025.03.19.642201 doi: [link] Recent years have seen an explosion in the prominence of covalent inhibitors as research and therapeutic tools. However, a lag in application of computational methods for covalent docking slows progress in this field. AI models such as AlphaFold3 have shown accuracy in ligand pose prediction but were never assessed for virtual screening.

article thumbnail

Millipedes make ants dizzy — and might soon treat human pain

Science Daily: Pharmacology News

Millipedes, often dismissed as creepy crawlies, may hold the secret to future painkillers and neurological drugs. Researchers at Virginia Tech discovered unique alkaloid compounds in the defensive secretions of a native millipede species. These complex molecules, which cause disorientation in ants, interact with human neuroreceptors linked to pain and cognition.

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Designing antibodies to think before they bind

Drug Target Review

Antibody therapies have transformed cancer treatment, yet their limits are becoming increasingly clear – particularly when tumours evolve, evade immune detection or develop resistance to existing drugs. For Dr Jhong-Jhe ‘JJ’ You, Vice President of Antibody Discovery at AP Biosciences, these challenges are not setbacks. They are starting points. With a background in neurobiology, immuno-oncology and bispecific engineering, JJ now leads the development of antibody candidates designed to go further

article thumbnail

Synthesis and Bioactivity Evaluation of Novel Sulfonamide‐1,2,3‐Triazole Hybrids: In Vitro and In Silico Studies

Chemical Biology and Drug Design

Novel 1,2,3-triazole derivatives incorporating a 4-iodosulfonamide moiety were synthesized. Their antioxidant properties were evaluated using DPPH, ABTS, and CUPRAC methods. The inhibitory activity of the compounds against cholinesterases (AChE and BuChE) was investigated. An investigation of their anticancer properties against Caco-2 and PC3 cancer cell lines was also conducted.

More Trending

article thumbnail

The plant virus that trains your immune system to kill cancer

Science Daily: Pharmacology News

A virus from humble black-eyed peas is showing extraordinary promise in the fight against cancer. Unlike other plant viruses, the cowpea mosaic virus (CPMV) can awaken the human immune system and transform it into a cancer-fighting powerhouse, without infecting human cells. By comparing it to a similar, but ineffective, virus, researchers uncovered that CPMV uniquely triggers potent interferons and immune responses, making it a low-cost, plant-grown immunotherapy on the fast track toward clinica

article thumbnail

From lab to clinic: the rise of Radio-DARPins in oncology

Drug Target Review

Radioligand therapy (RLT) has emerged as a powerful modality in oncology, offering highly targeted delivery of radiation to cancer cells while sparing healthy tissues. Although RLT has already demonstrated success in certain haematological and prostate cancers, its application in solid tumours has historically faced a number of biological and technical challenges – from limited tissue penetration to off-target toxicity, particularly in organs like the kidneys.

article thumbnail

A Visual Guide to Gene Delivery

Codon

A gene is the essential hereditary unit that passes traits from parents to offspring; a segment of DNA containing instructions for making a specific protein or molecule that performs a particular function in your body. And yet, despite being fundamental to our flourishing, genes can be broken. Researchers have identified nearly 10,000 monogenic diseases , or conditions caused by errors in a single gene.

article thumbnail

FDA Upgrades Recall on 160,000+ Bottles of Thyroid Medication

Drugs.com

THURSDAY, July 24, 2025 — The U.S. Food and Drug Administration (FDA) has upgraded a recall of a commonly prescribed thyroid medication due to what it described as "subpotent" active ingredients. The recall of more than 160,000 bottles of.

FDA
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Orelabrutinib, an irreversible inhibitor of Bruton’s tyrosine kinase, for the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, phase Ib/IIa study

Covalent Modifiers

Xue Li, Ru Li, Xiaoxia Zhu et al. Research Square Preprint, 23 July 2025, [link] Orelabrutinib is a highly selective, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). It has shown promising results in animal models, indicating potential for treating systemic lupus erythematosus (SLE). A multicentre, double-blind, randomised, placebo-controlled, phase Ib/IIa trial (NCT04305197) was conducted.

article thumbnail

This sugar substitute does more than sweeten — it kills cancer cells

Science Daily: Pharmacology News

Fermenting stevia with a banana leaf-derived probiotic turns it into a powerful cancer-fighting agent that kills pancreatic cancer cells while sparing healthy ones. The secret lies in a metabolite called CAME, produced through microbial transformation.

article thumbnail

Fixing failed drugs: AI solutions for toxicity in drug discovery – part 3

Drug Target Review

When discussing how newer AI technologies like large language models (LLMs) could contribute to toxicity prediction, Hosseini-Gerami identified two key applications: 1. Improved scientist–data interaction: “Once we have all these datasets, have run these algorithms and have some outcomes and outputs, how can a scientist really engage with that information and use it to make a decision on what to do next?

article thumbnail

Off-target toxicity in antibody-drug conjugates

Crown Bioscience

Antibody-drug conjugates (ADCs) are among the most exciting advances in target cancer therapy. They combine the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs to focus treatment on malignant cells while reducing damage to healthy cells.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Sygnature Discovery Completes Major Enhancement of High-Throughput Chemistry Facilities Following £1 Million Investment

Sygnature Discovery

Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure following a £1 million investment. In today’s demanding drug discovery landscape, accelerating time to value inflection remains a top industry priority.

article thumbnail

Insulin Nasal Spray Reaches Alzheimer's Targets, Brain Scans Show

Drugs.com

THURSDAY, July 24, 2025 — Insulin delivered by nasal spray might be a potential treatment for Alzheimer’s disease, a new study says. An insulin nasal spray effectively reached key memory regions in the brains of a small group of older.

article thumbnail

Ivermectin: The mosquito-killing pill that dropped malaria by 26%

Science Daily: Pharmacology News

A groundbreaking study has revealed that the mass administration of ivermectin—a drug once known for treating river blindness and scabies—can significantly reduce malaria transmission when used in conjunction with bed nets.

article thumbnail

Managing CGT trials: the role of IRT from discovery to clinical development

Drug Target Review

The journey of cell and gene therapies from preclinical discovery to clinical trials is complex and challenging, impacting every team member involved, from researchers in the lab to patients receiving treatment. As CGT trials require innovative and flexible solutions, the need for technology such as interactive response technology (IRT) has become crucial in streamlining trial workflows, ensuring data integrity, and maintaining regulatory compliance as therapies advance from preclinical stages.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Repurposing of FDA‐Approved Drugs to Disrupt Iron Uptake in Mycobacterium abscessus: Targeting Salicylate Synthase as a Novel Approach

Chemical Biology and Drug Design

A drug repurposing strategy was applied against M. abscessus, through a virtual screening of FDA approved drugs on salicylate synthase. Eleven potential ligands were found; among these, three were confirmed as potent inhibitors of the enzyme. ABSTRACT Non-tuberculous mycobacteria (NTM) are opportunistic pathogens that lead to severe, persistent infections, particularly in immunocompromised or vulnerable individuals.

article thumbnail

How Smarter API Manufacturing Is Eating Big Pharma’s Lunch

Drug Patent Watch

"The $100 Billion Shift: How Smarter API Manufacturing is Redefining the Pharmaceutical Industry As the pharma landscape continues to evolve, one thing is clear: the traditional model of big pharma dominance is no longer sustainable. A seismic shift is underway, driven by the rise of smarter API (Active Pharmaceutical Ingredient) manufacturing.

article thumbnail

Why More Data Hasn’t Improved Clinical Trial Enrollment

H1 Blog

More Information, Same Enrollment Challenges In clinical trial feasibility, we face a counterintuitive reality: despite unprecedented access to healthcare professional data, identifying the right investigators and predicting enrollment success has become increasingly challenging. This paradox, highlighted in a recent Life Sciences DNA podcast featuring Ariel Katz, co-founder and CEO of H1, in conversation with Dr.

article thumbnail

Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival

BioPharma Drive: Drug Pricing

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical tests and is building a manufacturing network in support.

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

FDA Approves First Cream for Treating Chronic Hand Eczema, Anzupgo

Drugs.com

THURSDAY, July 24, 2025 — The U.S. Food and Drug Administration (FDA) has signed off on the first-ever cream specifically approved for treating chronic hand eczema (CHE). CHE is common condition marked by redness, itching and cracking on the.

article thumbnail

Vamorolone

New Drug Approvals

Vamorolone CAS 13209-41-1 Molecular Weight 356.46 Formula C 22 H 28 O 4 Agamree 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione VBP-15 free alcohol (8 S ,10 S ,13 S ,14 S ,16 R ,17 R )-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6 H -cyclopenta[a]phenanthren-3-one (16alpha)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta

FDA
article thumbnail

Eight Key Considerations for Evaluating FSP Partners Offering Remote-Based Regional Hubs

PPD

Biopharma and biotech industries are facing remarkable challenges as the cost of developing new drugs has surged dramatically and clinical trial timelines have extended significantly. For example, over the past decade, the average time required to complete a clinical trial has increased by approximately 20-30%. These elongated timelines are contributing to soaring costs, with the average cost of developing a new drug rising to approximately $2.6 billion (versus $1-1.5 billion just a decade ago).

article thumbnail

CDD Vault Update (July #2 2025) Search Inventory by Molecule & Batch Fields, Protocol Plate Locations, Stoichiometry Table Debiting, Synonym Links in ELN, Chemical Properties in Structure Editor

Collaborative Drug

CDD Vault Update (July #2 2025) Search Inventory by Molecule & Batch Fields, Protocol Plate Locations, Stoichiometry Table Debiting, Synonym Links in ELN, Chemical Properties in Structure Editor

article thumbnail

Bain leads $300M investment in startup built on Bristol Myers immune drugs

BioPharma Drive: Drug Pricing

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five drugs that no longer fit its plans.

article thumbnail

Cracking the Code: Using Drug Patents to Reveal Competitor Formulation Strategies

Drug Patent Watch

Uncovering the Secret Formulas: How Drug Patents Reveal the Competition's Playbook As the pharmaceutical industry continues to evolve, companies are under increasing pressure to innovate and stay ahead of the curve. But what if the key to unlocking your competitors' strategies lies in plain sight – hidden in the complex web of drug patents? A new analysis from Drug Patent Watch reveals the surprising ways in which competitors are using patent data to inform their formulation strategies.

article thumbnail

Harnessing TnpB for Genome Editing: A Compact and Versatile Tool for Your Research

addgene Blog

This blog post was written by Dr. Kutubuddin Molla, investigator at ICAR-Central National Rice Research Institute. When it comes to genome editing, CRISPR is a name that resonates with nearly every biologist, academic, and researcher. Among the most well-known CRISPR-associated nucleases are Cas9 and Cas12a, the heavyweights in the genome editing toolbox.

article thumbnail

From Cost Cutter to Concierge: The Evolution of AI in Customer Experience

Perficient: Drug Development

For years, AI in customer service has been synonymous with efficiency. Businesses leaned on AI agents to reduce costs, deflect calls, and automate routine tasks. These agents were designed to streamline operations, not necessarily delight customers. But a new chapter is quickly unfolding. We’re now entering the era of agentic AI with a new generation of intelligent systems that don’t just respond to commands but act with purpose, context, and autonomy.

article thumbnail

Vault Snack #30 – Additional Curve Fits for Plotting and Analysing Assay Data in CDD Vault

Collaborative Drug

Skip to content Login Search { Products CDD Vault Why CDD Vault Core Functionality Registration Activity Visualization Assays Add-ons ELN Inventory Curves AI AI + Automation Solutions Applications Assay Data Management Macrocycle Protein Therapeutic CRISPR PROTAC Antibody Drug Conjugate Small Molecules & Mixtures Industries Biotech & Pharmaceutical CRO Academics Agritechnology Consortia & Collaborations Consumer Goods User Roles Research Scientist Operations/IT Legal/Regulatory Execu

article thumbnail

Merck plans spending shift to boost business beyond Keytruda

BioPharma Drive: Drug Pricing

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support of newer drugs and R&D.

article thumbnail

Drug candidate eliminates breast cancer tumors in mice in a single dose

Science Daily: Pharmacology News

Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women. Treatment typically involves surgery and follow-up hormone therapy, but late effects of these treatments include osteoporosis, sexual dysfunction and blood clots. Now, researchers have created a novel treatment that eliminated small breast tumors and significantly shrank large tumors in mice in a single dose, without problematic side effects.